摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(甲基磺酰基)苯-1-磺酰氯 | 5335-40-0

中文名称
3-(甲基磺酰基)苯-1-磺酰氯
中文别名
3-甲砜基苯磺酰氯
英文名称
3-(methylsulfonyl)benzenesulfonyl chloride
英文别名
3-(methylsulfonyl)benzene-1-sulfonyl chloride;3-methylsulfonylbenzenesulfonyl chloride
3-(甲基磺酰基)苯-1-磺酰氯化学式
CAS
5335-40-0
化学式
C7H7ClO4S2
mdl
MFCD04037968
分子量
254.715
InChiKey
CQEFJGDLGWJIRV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    93~96℃
  • 沸点:
    449.7±37.0 °C(Predicted)
  • 密度:
    1.517±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    85
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2904909090
  • 包装等级:
    III
  • 危险类别:
    8
  • 危险性防范说明:
    P260,P280,P303+P361+P353,P301+P330+P331,P304+P340+P310,P305+P351+P338+P310
  • 危险品运输编号:
    3261
  • 危险性描述:
    H314

SDS

SDS:e7436e86bb2d109b89b3b8171b307abf
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-(Methylsulfonyl)benzenesulfonyl chloride
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Methylsulfonyl)benzenesulfonyl chloride
CAS number: 5335-40-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H7ClO4S2
Molecular weight: 254.7

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述:3-甲砜基苯磺酰氯可用作医药合成中间体。如吸入该物质,请将患者移至空气新鲜处;若皮肤接触到此物质,应脱去污染的衣物,并用肥皂水和清水彻底冲洗皮肤。如有不适,请及时就医。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(甲基磺酰基)苯-1-磺酰氯羟胺 作用下, 以 四氢呋喃 为溶剂, 以60%的产率得到N-hydroxy-3-methanesulfonylbenzene-1-sulfonamide
    参考文献:
    名称:
    NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX
    摘要:
    所披露的主题提供了N-取代羟胺衍生物化合物、含有这些化合物的药物组合物和配套工具包,以及使用这些化合物或药物组合物的方法。具体而言,所披露的主题提供了使用这些化合物或药物组合物治疗心力衰竭的方法。
    公开号:
    US20140206769A1
  • 作为产物:
    描述:
    苯甲砜氯磺酸 作用下, 以 氯磺酸 为溶剂, 反应 18.0h, 以75%的产率得到3-(甲基磺酰基)苯-1-磺酰氯
    参考文献:
    名称:
    NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX
    摘要:
    所披露的主题提供了N-取代羟胺衍生物化合物、含有这些化合物的药物组合物和配套工具包,以及使用这些化合物或药物组合物的方法。具体而言,所披露的主题提供了使用这些化合物或药物组合物治疗心力衰竭的方法。
    公开号:
    US20140206769A1
点击查看最新优质反应信息

文献信息

  • BORON-CONTAINING SMALL MOLECULES
    申请人:Xia Yi
    公开号:US20100256092A1
    公开(公告)日:2010-10-07
    This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.
    这项发明涉及6-取代苯硼酯化合物等物品,以及它们用于治疗细菌感染的用途。
  • Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist
    作者:Xishan Wu、Hui Shen、Yan Zhang、Chao Wang、Qiu Li、Cheng Zhang、Xiaoxi Zhuang、Chenchang Li、Yudan Shi、Yanli Xing、Qiuping Xiang、Jinxin Xu、Donghai Wu、Jinsong Liu、Yong Xu
    DOI:10.1021/acs.jmedchem.1c00763
    日期:2021.6.24
    (IC50) value of 64 nM and showed excellent selectivity against other nuclear receptors. 27h also potently suppressed cell proliferation, colony formation, and the expression of androgen receptor (AR)-regulated genes in AR-positive prostate cancer cell lines. In addition, 27h demonstrated good metabolic stability and a pharmacokinetic property with reasonable oral bioavailability (32.41%) and moderate half-life
    受体相关孤儿受体γ(RORγ)已成为治疗癌症和炎症性疾病的一个有吸引力的治疗靶点。在此,我们报告了我们在苯并噻唑和苯并咪唑衍生物作为 RORγ 新型反向激动剂的发现、优化和评估方面所做的努力。代表性化合物27h (命名为XY123)有效抑制RORγ转录活性,半数抑制浓度(IC 50 )值为64 nM,并对其他核受体表现出优异的选择性。 27h还有效抑制 AR 阳性前列腺癌细胞系中的细胞增殖、集落形成和雄激素受体 (AR) 调节基因的表达。此外, 27h表现出良好的代谢稳定性和药代动力学特性,具有合理的口服生物利用度 (32.41%) 和中等的半衰期 ( t 1/2 = 4.98 h)。值得注意的是,口服化合物27h在小鼠22Rv1异种移植肿瘤模型中实现了完全且持久的肿瘤消退。化合物27h可能作为一种新的有价值的先导化合物,用于进一步开发治疗前列腺癌的药物。
  • 5-Membered heterocyclic compound
    申请人:Nishida Haruyuki
    公开号:US20090156642A1
    公开(公告)日:2009-06-18
    The present invention provides 5-membered heterocycle compounds represented by the following general formula (I): The present compounds have a superior acid secretion inhibitory effect, and shows an antiulcer activity and the like.
    本发明提供了以下通式(I)表示的5元杂环化合物: 本化合物具有优异的抑制胃酸分泌效果,并显示出抗溃疡活性等。
  • [EN] SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF<br/>[FR] PETITES MOLÉCULES AGONISTES DE LA MUCOLIPINE 1 ET LEURS UTILISATIONS
    申请人:UNIV MICHIGAN REGENTS
    公开号:WO2021041866A1
    公开(公告)日:2021-03-04
    This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.
    这项发明属于药物化学领域。特别是,该发明涉及一类新的小分子,具有苯磺酰胺(或类似)结构,作为肌球脂蛋白1(ML1)的激动剂,以及它们作为治疗杜氏肌肉萎缩症(DMD)和相关疾病的疗法的用途。
  • [EN] MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS<br/>[FR] INHIBITEURS DE MTH1 DESTINÉS AU TRAITEMENT DES ÉTATS INFLAMMATOIRES ET AUTO-IMMUNS
    申请人:THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING
    公开号:WO2015187089A1
    公开(公告)日:2015-12-10
    A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    化合物的化学式(I),或其药学上可接受的盐,用于治疗自身免疫性疾病和炎症性疾病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐